A Smarter IV Catheter Could Make Hospital Care Safer: Why Biomaterials Matter

Makassar, Indonesia, July 13, 2026/MWM-RG/ – Every day, millions of patients around the world receive intravenous (IV) therapy for medications, fluids, or blood transfusions. Although this procedure is considered routine, it is not always risk-free. One of the most common complications is phlebitis, an inflammation of the vein that can cause pain, swelling, redness, infection, prolonged hospitalization, and increased healthcare costs. Surprisingly, the material used to manufacture an IV catheter may significantly influence whether this complication occurs.

This important finding comes from an article entitled “Effectiveness of Ethylene Tetrafluoroethylene (ETFE) and Polypropylene (PP) Peripheral Intravenous Catheter Biomaterials on the Incidence of Phlebitis,” published in the Journal of Infusion Nursing, issued by Lippincott Williams & Wilkins (LWW) in April 2026. The study compared two widely used catheter biomaterials Ethylene Tetrafluoroethylene (ETFE) and Polypropylene (PP) to determine which provides better protection against phlebitis among hospitalized patients.

The researchers discovered that patients using ETFE catheters experienced milder phlebitis and significantly lower bacterial colonization than those using PP catheters. While both materials performed similarly regarding the overall duration before phlebitis developed, ETFE consistently demonstrated better biological compatibility with human tissues. Its smoother surface and lower friction reduce irritation to the vein wall, helping minimize inflammation and bacterial growth. These findings suggest that selecting the right biomaterial is not merely a technical decision but an essential component of improving patient safety.

For nurses and healthcare providers, this research highlights an important opportunity to strengthen evidence-based clinical practice. Choosing safer catheter materials can reduce complications, improve patient comfort, decrease treatment interruptions, and potentially lower hospital expenses. Small improvements in medical device selection can create meaningful differences in healthcare quality, especially in hospitals where IV therapy is performed daily.

Beyond hospitals, this study reminds us that innovation in healthcare often happens behind the scenes. Advances in biomaterials rarely receive public attention, yet they play a crucial role in making medical treatments safer and more effective. Scientific discoveries like these demonstrate that healthcare innovation is not limited to new medicines or sophisticated machines it also includes improving everyday medical devices that millions of patients rely on.

This research directly supports Sustainable Development Goal (SDG) 3: Good Health and Well-being, which promotes healthy lives and quality healthcare for all. By reducing preventable complications associated with intravenous therapy, better biomaterials contribute to safer hospitals, higher standards of nursing care, and improved patient outcomes. Investing in safer medical technologies also strengthens healthcare systems and supports the global commitment to delivering high-quality, patient-centered care.

Ultimately, the message is simple but powerful: sometimes, the smallest component of a medical device can make one of the biggest differences. Selecting the right catheter biomaterial may seem like a minor clinical choice, but it has the potential to protect patients, improve recovery, and advance the future of safe healthcare worldwide.

Reference:
DOI. https://doi.org/10.1097/NAN.0000000000000648

Contact:
Dr. Takdir Tahir, S.Kep.,NS.,M.Kes.
628164384948
takdirtahir@unhas.ac.id